Preclinical Evaluation of Sodium Selenite in Mice: Toxicological and Tumor Regression Studies after Striatum Implantation of Human Glioblastoma Stem Cells
Authors:
- Louis LarrouquèreLLLouis Larrouquère
- Sylvie BerthierSBSylvie Berthier
- Benoit ChovelonBCBenoit Chovelon
- Catherine GarrelCGCatherine Garrel
- Véronique VacchinaVVVéronique Vacchina
- Hugues PaucotHPHugues Paucot
- Jean BoutonnatJBJean Boutonnat
- Patrice FaurePFPatrice Faure
- Florence Hazane-PuchFHFlorence Hazane-Puch
Open Access
- 30 September 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (19) , 10646
Abstract
Glioblastoma (GBM) is the most aggressive malignant glioma, with a very poor prognosis; as such, efforts to explore new treatments and GBM’s etiology are a priority. We previously described human GBM cells (R2J-GS) as exhibiting the properties of cancer stem cells (growing in serum-free medium and proliferating into nude mice when orthotopically grafted). Sodium selenite (SS)—an in vitro attractive agent for cancer therapy against GBM—was evaluated in R2J-GS cells. To go further, we launched a preclinical study: SS was given orally, in an escalation-dose study (2.25 to 10.125 mg/kg/day, 5 days on, 2 days off, and 5 days on), to evaluate (1) the absorption of selenium in plasma and organs (brain, kidney, liver, and lung) and (2) the SS toxicity. A 6.75 mg/kg SS dose was chosen to perform a tumor regression assay, followed by MRI, in R2J-GS cells orthotopically implanted in nude mice, as this dose was nontoxic and increased brain selenium concentration. A group receiving TMZ (5 mg/kg) was led in parallel. Although not reaching statistical significance, the group of mice treated with SS showed a slower tumor growth vs. the control group (p = 0.08). No difference was observed between the TMZ and control groups. We provide new insights of the mechanisms of SS and its possible use in chemotherapy.Keywords
Funding Information
- Groupement des Entreprises Françaises dans la lutte contre le Cancer (2018-2019)
This publication has 57 references indexed in Scilit:
- RhoA modulates functional and physical interaction between ROCK1 and Erk1/2 in selenite-induced apoptosis of leukaemia cellsCell Death & Disease, 2013
- Current Strategies for Identification of Glioma Stem Cells: Adequate or Unsatisfactory?Journal of Oncology, 2012
- Stability of temozolomide in solutions aimed for oral treatment prepared from a commercially available powder for infusionPharmaceutical Methods, 2012
- In vitro expansion of human glioblastoma cells at non-physiological oxygen tension irreversibly alters subsequent in vivo aggressiveness and AC133 expressionInternational Journal of Oncology, 2011
- Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult BrainCancer Cell, 2011
- Selenoprotein P—Expression, functions, and roles in mammalsBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- Extracellular thiol-assisted selenium uptake dependent on the x c − cystine transporter explains the cancer-specific cytotoxicity of seleniteProceedings of the National Academy of Sciences, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005